A Phase II study of 13-cis-retinoic acid in patients with advanced renal cell carcinoma

被引：30
|
作者：
Berg, WJ
Schwartz, LH
Amsterdam, A
Mazumdar, M
Vlamis, V
Law, TM
Nanus, DM
Motzer, RJ
机构：
[1] Mem Sloan Kettering Canc Ctr, Div Solid Tumor Oncol, Genitourinary Oncol Serv, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Radiol, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Biostat & Epidemiol, New York, NY 10021 USA
[4] Mem Sloan Kettering Canc Ctr, Genitourinary Oncol Res Lab, New York, NY 10021 USA
[5] Cornell Univ, Coll Med, Dept Med, New York, NY USA
来源：
INVESTIGATIONAL NEW DRUGS | 1997年 / 15卷 / 04期
关键词：
advanced renal cell carcinoma; retinoic acid;
D O I：
10.1023/A:1005902022076
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The aim of this study was to determine the antitumor activity of 13-cis-retinoic acid as a single agent in patients with advanced renal cell carcinoma. Eligible patients had advanced renal cell carcinoma with bi-dimensionally measurable disease, a Karnofsky performance status of at least 70, life expectancy of greater than three months, no evidence of brain metastases, and treatment with no more than one chemotherapy regimen. Patients were treated with one mg/kg/day of 13-cis-retinoic acid orally. Twenty-six patients were enrolled in this study and 25 were evaluable for response and toxicity. Of the twenty-five evaluable patients, no major responses were achieved. Toxicity was mild, with no patient requiring a dose reduction. At the dose administered in this trial, 13-cis-retinoic acid is inactive as a single agent in renal cell carcinoma.
引用
收藏
页码：353 / 355
页数：3
相关论文
共 50 条
  • [21] 13-CIS-RETINOIC ACID FOR ACNE
    SHUSTER, S
    LANCET, 1979, 2 (8132): : 50 - 50
  • [22] Disorder in 13-cis-Retinoic acid
    Malpezzi, L
    Fuganti, C
    Grasselli, P
    ACTA CRYSTALLOGRAPHICA SECTION C-CRYSTAL STRUCTURE COMMUNICATIONS, 1997, 53 : 508 - 511
  • [23] 13-CIS-RETINOIC ACID AND TETRACYCLINE VERSUS 13-CIS-RETINOIC ACID ALONE IN THE TREATMENT OF NODULOCYSTIC ACNE
    LANGNER, A
    WOLSKA, H
    FRACZYKOWSKA, M
    JABLONSKA, S
    MAJEWSKI, S
    DERMATOLOGICA, 1985, 170 (04): : 185 - 188
  • [24] Results of a phase II pilot study of 13-cis-retinoic acid with gemcitabine in patients with unresectable pancreatic cancer.
    Michael, A
    Maraveyas, A
    Hill, M
    Dalgleish, A
    Lofts, F
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 361S - 361S
  • [25] Clinical and in vitro response to 13-cis-retinoic acid in interferon-alpha resistant renal cell carcinoma
    Buer, J
    Probst, M
    Duensing, S
    Koditz, H
    Franzke, A
    Dallmann, I
    Ganser, A
    Atzpodien, J
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 1997, 12 (03) : 143 - 147
  • [26] Interferon alpha-2a and 13-cis-retinoic acid in patients with metastatic renal cell cancer
    Jacobs, A
    Gold, P
    Weiden, P
    Aboulafia, D
    Rudolph, R
    Picozzi, V
    Thompson, J
    CANCER INVESTIGATION, 2000, 18 (05) : 417 - 421
  • [27] PHASE-II STUDY OF ALPHA-INTERFERON AND 13-CIS-RETINOIC ACID IN METASTATIC MELANOMA
    DHINGRA, K
    PAPADOPOULOS, N
    LIPPMAN, S
    LOTAN, R
    LEGHA, SS
    INVESTIGATIONAL NEW DRUGS, 1993, 11 (01) : 39 - 43
  • [28] Treatment of unresectable recurrent head and neck carcinoma with 13-cis-retinoic acid and interferon-alpha. A phase II study
    Nikolaou, AC
    Fountzilas, G
    Daniilidis, I
    JOURNAL OF LARYNGOLOGY AND OTOLOGY, 1996, 110 (09): : 857 - 861
  • [29] PHASE II TRIAL OF 13-CIS-RETINOIC ACID IN METASTATIC BREAST-CANCER
    CASSIDY, J
    LIPPMAN, M
    LACROIX, A
    PECK, G
    EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1982, 18 (10): : 925 - 928
  • [30] RESPONSE TO 13-CIS-RETINOIC ACID PLUS INTERFERON ALFA-2A IN 2 PATIENTS WITH THERAPY-REFRACTORY ADVANCED RENAL-CELL CARCINOMA
    BUER, J
    PROBST, M
    GANSER, A
    ATZPODIEN, J
    JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (10) : 2679 - 2680
12345